Hyperprolactinemia and cancer risk: a Swedish population-based cohort study.

IF 2.8 3区 医学 Q3 ENDOCRINOLOGY & METABOLISM
Endocrine Connections Pub Date : 2025-06-19 Print Date: 2025-06-01 DOI:10.1530/EC-25-0108
Christos Himonakos, Louise Emilsson, Sophie Bensing, Katarina Berinder
{"title":"Hyperprolactinemia and cancer risk: a Swedish population-based cohort study.","authors":"Christos Himonakos, Louise Emilsson, Sophie Bensing, Katarina Berinder","doi":"10.1530/EC-25-0108","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Prolactin (PRL) promotes cell proliferation, and PRL receptor expression is elevated in various cancer types. However, only a few studies have examined cancer risk in patients with hyperprolactinemia (HPL). The aim of this study was to investigate cancer risk in a nationwide cohort of patients with a diagnosis of HPL, with special emphasis on breast cancer.</p><p><strong>Design: </strong>In this Swedish population-based cohort study, we used nationwide registries to identify 3,837 patients (2,955 (77%) women) with HPL, treated with dopamine agonists (DA), diagnosed between 2006 and 2019, along with 38,370 controls matched by age, sex, calendar year and county of residence at first HPL diagnosis.</p><p><strong>Methods: </strong>Cancer outcomes (overall and specific types), as registered in the Swedish Cancer Register, were analyzed using Cox regression, internally stratified by the matching variables and additionally adjusted for diabetes mellitus, obesity, smoking, alcohol overconsumption, hormone replacement therapy and educational level to estimate adjusted hazard ratios (aHRs).</p><p><strong>Results: </strong>During a median follow-up time of 6.1 years (interquartile range (IQR) 3.4-9.6), 168 (4.6%) new cases of cancer were identified in patients with HPL and 1,608 (4.4%) in the control group (aHR 1.05 (95% CI: 0.89-1.23)). Twenty-eight (0.7%) patients (all women) in the HPL group and 267 (0.7%) in the control group developed breast cancer (aHR 1.02 (95% CI: 0.68-1.51)). Similarly, there was no increased risk of any other site-specific cancer.</p><p><strong>Conclusions: </strong>In this nationwide cohort study of patients with DA-treated HPL, no increased risk of overall cancer, breast cancer or other site-specific malignancies was observed.</p>","PeriodicalId":11634,"journal":{"name":"Endocrine Connections","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12186297/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine Connections","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1530/EC-25-0108","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/1 0:00:00","PubModel":"Print","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Prolactin (PRL) promotes cell proliferation, and PRL receptor expression is elevated in various cancer types. However, only a few studies have examined cancer risk in patients with hyperprolactinemia (HPL). The aim of this study was to investigate cancer risk in a nationwide cohort of patients with a diagnosis of HPL, with special emphasis on breast cancer.

Design: In this Swedish population-based cohort study, we used nationwide registries to identify 3,837 patients (2,955 (77%) women) with HPL, treated with dopamine agonists (DA), diagnosed between 2006 and 2019, along with 38,370 controls matched by age, sex, calendar year and county of residence at first HPL diagnosis.

Methods: Cancer outcomes (overall and specific types), as registered in the Swedish Cancer Register, were analyzed using Cox regression, internally stratified by the matching variables and additionally adjusted for diabetes mellitus, obesity, smoking, alcohol overconsumption, hormone replacement therapy and educational level to estimate adjusted hazard ratios (aHRs).

Results: During a median follow-up time of 6.1 years (interquartile range (IQR) 3.4-9.6), 168 (4.6%) new cases of cancer were identified in patients with HPL and 1,608 (4.4%) in the control group (aHR 1.05 (95% CI: 0.89-1.23)). Twenty-eight (0.7%) patients (all women) in the HPL group and 267 (0.7%) in the control group developed breast cancer (aHR 1.02 (95% CI: 0.68-1.51)). Similarly, there was no increased risk of any other site-specific cancer.

Conclusions: In this nationwide cohort study of patients with DA-treated HPL, no increased risk of overall cancer, breast cancer or other site-specific malignancies was observed.

Abstract Image

Abstract Image

Abstract Image

高泌乳素血症与癌症风险:一项瑞典人群队列研究
目的:催乳素(Prolactin, PRL)促进细胞增殖,PRL受体在多种肿瘤中表达升高。然而,只有少数研究检查了高泌乳素血症(HPL)患者的癌症风险。本研究的目的是调查全国范围内诊断为HPL的患者的癌症风险,特别强调乳腺癌。设计:在这项以瑞典人口为基础的队列研究中,我们使用全国登记系统,确定了2006年至2019年间诊断的3837例HPL患者(2955例[77%]女性),接受多巴胺激动剂(DA)治疗,以及38370例对照,这些对照与首次HPL诊断时的年龄、性别、日历年和居住地相匹配。方法:使用Cox回归分析在瑞典癌症登记处登记的癌症结局(总体和特定类型),通过匹配变量进行内部分层,并对糖尿病、肥胖、吸烟、饮酒过量、激素替代疗法和教育水平进行调整,以估计调整后的风险比(aHRs)。结果:中位随访时间为6.1年(四分位数间距[IQR] 3.4-9.6), HPL患者中发现168例(4.6%)新发癌症病例,对照组中发现1608例(4.4%)(aHR为1.05 [95% CI: 0.89-1.23])。HPL组28例(0.7%)患者(均为女性)和对照组267例(0.7%)患者发生乳腺癌(aHR为1.02 [95% CI: 0.68-1.51])。同样,没有增加任何其他部位特异性癌症的风险。结论:在这项针对da治疗的HPL患者的全国性队列研究中,未观察到总体癌症、乳腺癌或其他部位特异性恶性肿瘤的风险增加。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Endocrine Connections
Endocrine Connections Medicine-Internal Medicine
CiteScore
5.00
自引率
3.40%
发文量
361
审稿时长
6 weeks
期刊介绍: Endocrine Connections publishes original quality research and reviews in all areas of endocrinology, including papers that deal with non-classical tissues as source or targets of hormones and endocrine papers that have relevance to endocrine-related and intersecting disciplines and the wider biomedical community.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信